These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Effects of apomorphine on morphine analgesia during the state of dopaminergic supersensitivity after chronic treatment with haloperidol. Kamata K; Ogawa K; Noma S; Kameyama T J Pharmacobiodyn; 1986 Jan; 9(1):88-94. PubMed ID: 3712211 [TBL] [Abstract][Full Text] [Related]
84. SCH 23390, a selective dopamine D1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine. Mereu G; Collu M; Ongini E; Biggio G; Gessa GL Eur J Pharmacol; 1985 May; 111(3):393-6. PubMed ID: 3894035 [TBL] [Abstract][Full Text] [Related]
86. Distinct effects of two stresses on the behavioral response to apomorphine. Csernansky JG; Csernansky CA; Hollister LE Life Sci; 1984 Oct; 35(14):1513-8. PubMed ID: 6541282 [TBL] [Abstract][Full Text] [Related]
87. Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat. Deutsch SI; Halperin R; Stanley M; Davis KL Neurochem Res; 1985 Apr; 10(4):491-8. PubMed ID: 2582289 [TBL] [Abstract][Full Text] [Related]
88. Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis. Morelli M; Longoni R; Spina L; Di Chiara G Psychopharmacology (Berl); 1986; 89(2):259-60. PubMed ID: 3088647 [TBL] [Abstract][Full Text] [Related]
89. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Cohen BM; Tsuneizumi T; Baldessarini RJ; Campbell A; Babb SM Psychopharmacology (Berl); 1992; 108(3):338-44. PubMed ID: 1355924 [TBL] [Abstract][Full Text] [Related]
90. Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Salamone J; Baskin P Pharmacol Biochem Behav; 1996 Jan; 53(1):179-83. PubMed ID: 8848448 [TBL] [Abstract][Full Text] [Related]
92. Differential effects of dopamine agonists in mature and immature rats. McDevitt JT; Setler PE Eur J Pharmacol; 1981 Jun; 72(1):69-75. PubMed ID: 6973482 [TBL] [Abstract][Full Text] [Related]
93. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia. Yarbrough GG; Faison EP; Antolik EK Neurosci Lett; 1982 Dec; 34(3):321-3. PubMed ID: 6819493 [TBL] [Abstract][Full Text] [Related]
94. Inhibition of apomorphine-induced climbing in mice by cholinergic drugs and neuroleptics. Lassen JB Acta Pharmacol Toxicol (Copenh); 1979 Aug; 45(2):161-5. PubMed ID: 40391 [TBL] [Abstract][Full Text] [Related]
95. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. Ohno Y; Ishida K; Ishibashi T; Ikeda K; Kato T; Nakamura M Gen Pharmacol; 1995 May; 26(3):489-94. PubMed ID: 7789721 [TBL] [Abstract][Full Text] [Related]
96. Apomorphine-induced alterations in cortical EEG activity of rats. Involvement of D-1 and D-2 dopamine receptors. Kropf W; Kuschinsky K; Krieglstein J Naunyn Schmiedebergs Arch Pharmacol; 1989 Dec; 340(6 Pt 2):718-25. PubMed ID: 2699354 [TBL] [Abstract][Full Text] [Related]
97. Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. Arnt J; Christensen AV Eur J Pharmacol; 1981 Jan; 69(1):107-11. PubMed ID: 6110555 [TBL] [Abstract][Full Text] [Related]
99. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia. Gattaz WF; Emrich A; Behrens S J Neural Transm Gen Sect; 1993; 92(2-3):197-201. PubMed ID: 8369109 [TBL] [Abstract][Full Text] [Related]
100. Behavioral supersensitivity to apomorphine following chronic narcotic treatment in the guinea pig. Carlson KR; Almasi J Psychopharmacology (Berl); 1978 May; 57(3):273-7. PubMed ID: 97708 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]